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Abstract
Rearranged during transfection (RET), in complex with glial cell line-derived (GDNF) family receptor alpha (GFRα), is the
canonical signaling receptor for GDNF family ligands (GFLs) expressed in both central and peripheral parts of the nervous
system and also in non-neuronal tissues. RET-dependent signaling elicited by GFLs has an important role in the development,
maintenance and survival of dopamine and sensory neurons. Both Parkinson’s disease and neuropathic pain are devastating
disorders without an available cure, and at the moment are only treated symptomatically. GFLs have been studied extensively in
animal models of Parkinson’s disease and neuropathic pain with remarkable outcomes. However, clinical trials with recombinant
or viral vector-encoded GFL proteins have produced inconclusive results. GFL proteins are not drug-like; they have poor
pharmacokinetic properties and activate multiple receptors. Targeting RET and/or GFRα with small molecules may resolve
the problems associated with using GFLs as drugs and can result in the development of therapeutics for disease-modifying
treatments against Parkinson’s disease and neuropathic pain.
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Neurotrophic factors
Neurotrophic factors are a family of small secretory pro-
teins which are necessary for survival and maintenance of
both developing and mature neurons (Lanni et al. 2010).
The key feature for the protein to be classified as a neu-
rotrophic factor is the ability to promote the survival of
certain neuronal population(s). Neurotrophic factors pre-
vent neurodegeneration (Aron and Klein 2011), promote
axonal growth (Kramer et al. 2006), and maintain synap-
tic plasticity and behavior (Lo 1995; Lewin and Barde
1996; Gómez-Palacio-Schjetnan and Escobar 2013).
Neurotrophic factors are secreted into the extracellular
space and, following neuronal innervation, they can be
trafficked both in a retrograde and an anterograde manner
(Altar and DiStefano 1998; Reynolds et al. 2000).
Secreted neurotrophic factors act via receptors that are
expressed in both peripheral and central nervous systems,
activating intracellular signalling cascades important for
neuronal survival and functioning (Chang et al. 2019).
Neurotrophic factors include neurotrophins, glial cell
line-derived neurotrophic factor (GDNF) family ligands
(GFLs), neurokines, and the mesencephalic astrocyte-
derived neurotrophic factor/cerebral dopamine neuro-
trophic factor (MANF/CDNF) protein family. This review
is focused on GFLs which are distant members of the
transforming growth factor-β (TGF-beta) superfamily
and their receptors. The GFLs consist of four proteins:
GDNF, neurturin (NRTN), artemin (ARTN), and
persephin (PSPN). They have conserved patterns of seven
cysteine residues and function as homodimers (Eigenbrot
and Gerber 1997). They all mainly transmit signals via
transmembrane rearranged during transfection (RET)
through binding to one of its preferential cognate co-re-
ceptors, GDNF family receptor alpha (GFRα), but can
also act via neural cell adhesion molecule (NCAM)
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(Paratcha et al. 2003; Ilieva et al. 2019) and syndecan-3
(Bespalov et al. 2011).
GDNF family ligand receptors
RET was identified as an oncogenic protein activated by chro-
mosomal rearrangement (Takahashi et al. 1985; Takahashi
and Cooper 1987; Takahashi 2001). RET has a unique extra-
cellular domain consisting of four cadherin-like repeats, called
cadherin-like domains CLD1–4, and a calcium-binding site
between CLD2 and CLD3 (Anders et al. 2001). Calcium bind-
ing is necessary for the proper folding of RET and ligand
binding (Anders et al. 2001; Ibáñez 2013). Proximal to the
cadherin-like domains is the cysteine-rich region, which is
further connected to the transmembrane domain. The
cysteine-rich domain is necessary for ligand binding and prop-
er protein confirmation (Amoresano et al. 2005). The trans-
membrane domain is required for dimerization of RET and is
further linked to the intracellular domain. The intracellular
domain consists of a juxtamembrane portion, a tyrosine kinase
domain, and a C-terminal tail. Upon RET activation, multiple
tyrosines in the RET intracellular domain become phosphor-
ylated and serve as docking sites for adaptor proteins or en-
zymes needed for activation of downstream signalling cas-
cades promoting cell growth, proliferation, survival, and dif-
ferentiation (Airaksinen and Saarma 2002).
GFLs signal through transmembrane receptor tyrosine ki-
nase RET via forming a tripartite complex. The signalling
complex comprises two molecules of the RET receptor, two
molecules of glycosylphosphatidylinositol-linked GFRα, and
a dimeric ligand (Trupp et al. 1996; Durbec et al. 1996;
Treanor et al. 1996). The presence of co-receptors provides
specificity for ligand binding to a receptor complex. GDNF
preferentially binds to GFRα1, NRTN to GFRα2, ARTN to
GFRα3, and PSPN to GFRα4 (Airaksinen and Saarma 2002)
(Fig. 1). However, there is cross-talk between ligand and co-
receptors; for example, GDNF can also bind to GFRα2 and
NRTN can in turn bind to GFRα1 (Bespalov and Saarma
2007). Further, there is experimental evidence that ARTN
and PSPN can also interact with GFRα1 (Baloh et al. 1998;
Sidorova et al. 2010).
GFLs may also signal RET-independently through
NCAM which requires the presence of a GFRα co-
receptor (Paratcha et al. 2003) and heparan sulfate proteo-
glycan syndecan-3 (Bespalov et al. 2011). The interaction
of GFRα1 with NCAM downregulates NCAM-mediated
cell adhesion independently of GDNF (Ibáñez 2010). The
presence of GFRα1 potentiates the interaction of GDNF to
NCAM and activates cytoplasmic tyrosine kinases Fyn and
FAK which is necessary for Schwann cell migration and
axonal growth in hippocampal and cortical neurons
(Paratcha et al. 2003). Further, both NRTN and ARTN
mediate release of immunoreactive calcitonin gene-
related peptide (CGRP) through NCAM (Schmutzler
et al. 2011). Syndecan-3 was found to be a receptor for
GDNF, NRTN, and ARTN and promotes cell spreading
and neurite outgrowth of hippocampal neurons indepen-
dently from GFRα co-receptors (Bespalov et al. 2011).
Growth differentiation factor-15 (GDF-15), which is a dis-
tant member of the TGF-beta family, activates RET via
forming a complex with GDNF receptor alpha-like
(GFRΑL) and helps to regulate food intake, energy expendi-
ture, and body weight (Hsu et al. 2017; Mullican et al. 2017;
Yang et al. 2017), but may also play a role in the development
and survival of dopamine and sensory neurons (Strelau et al.
2009).
Parkinson’s disease
Parkinson’s disease (PD) is the second most common neuro-
degenerative disease affecting 2–3% of the population ≥
65 years of age (Poewe et al. 2017). The incidence of PD
increases with age and the disease is more common in males
(Miller and Cronin-Golomb 2010). It is a progressive neuro-
degenerative disorder which is characterized by the loss of
dopamine neurons in the substantia nigra pars compacta
(SNpc) (Dauer and Przedborski 2003). The loss of dopamine
neurons leads to striatal dopamine deficiency causing motor
impairment. The motor symptoms include bradykinesia, rigid-
ity, resting tremor, and postural instability (Kravitz et al.
2010). PD is also associated with many non-motor symptoms
such as hyposmia, depression, constipation, sleep disorders,
pain, lack of motivation, and cognitive problems which in-
creases disability for the patient (Postuma et al. 2012;
Duncan et al. 2014). It is estimated that 30% of cell bodies
and 80% of striatal dopamine axons are lost before the first
symptoms of PD appear (Burke and O’Malley 2013) (Fig. 2).
The molecular mechanism in the loss of dopamine neurons
involves multiple pathways, which include α-synuclein
(αSyn) proteostasis, mitochondrial function, oxidative stress,
calcium homeostasis, axonal transport, and neuroinflamma-
tion (Poewe et al. 2017). The pathological hallmark feature
of PD is the presence of Lewy bodies (LBs) in the brain. LB
includes a variety of intracellular proteins, among whichαSyn
is the most abundant component of the inclusion (Spillantini
et al. 1997). Recently, it was shown that LBs consist of a
crowded mix of fragmented membranes, organelles, and ves-
icles and the process of LB formation is considered as the
major process in the pathogenesis of PD (Shahmoradian
et al. 2019). Currently, treatment of PD is based on pharma-
cological substitution of dopamine, administration of dopa-
mine receptor agonists, and reduction of dopamine breakdown
by supplying monoamine oxidase B inhibitors (Schapira and
Olanow 2008). Further, deep brain stimulation is also
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recommended as an effective therapy for many neurological
diseases including PD (Fang and Tolleson 2017). The avail-
able therapies can neither halt nor reverse the disease progres-
sion, have significant side effects, almost no effect on non-
motor symptoms, and lose their efficacy with time. Therefore,
there is an immense need to develop therapies for the disease-
modifying management of PD.
GFLs in Parkinson’s disease
GFLs are potent neurotrophic factors for the survival of dopa-
mine neurons (Airaksinen and Saarma 2002). GDNF was the
first member from the GFLs discovered to be the survival
factor of dopamine neurons (Lin et al. 1993). NRTN,
ARTN, PSPN, and GDF15 are also known to promote the
survival of dopamine neurons both in vitro and in vivo
(Horger et al. 1998; Strelau et al. 2000; Zihlmann et al.
2005). Comparative studies on various neurotrophic factors
suggest that GDNF and NRTN are the most potent survival
factors for dopamine neurons (Zihlmann et al. 2005).
Moreover, the pattern of GFRα co-receptor expression and
cross-reactivity of GFLs to GFRα co-receptors are in line with
their survival-promoting properties in dopamine neurons.
Therefore, both GDNF and NRTN have been extensively
studied in various toxin-based models of PD in rodents and
primates and showed remarkable neuroprotective and
neurorestorative properties (Hoffer et al. 1994; Bowenkamp
et al. 1995; Beck et al. 1995; Gash et al. 1996; Horger et al.
1998; Kirik et al. 2000; Kordower et al. 2000; Oiwa et al.
2002; Runeberg-Roos et al. 2016). Further, overexpression
of both ARTN and PSPN in the mouse striatum and substantia
nigra either by lentiviral gene transfer or by neural stem cell
delivery prevents the degeneration of dopamine neurons
(Rosenblad et al. 2000; Åkerud et al. 2002; Yin et al. 2014).
Human dopamine neurons highly express RET, GFRα1,
and GFRα2 that are cognate receptors for GDNF and NRTN,
respectively (Runeberg-Roos et al. 2016). In rodents, the ex-
pression of GFRα2 is much weaker compared to GFRα1 in
the substantia nigra pars compacta (Horger et al. 1998; Wang
et al. 2000). GFRα3 is expressed in peripheral nerves and
ganglia, but not in the brain (Widenfalk et al. 1998;
Fig. 1 Neurotrophic factors and their receptors. GDNF family ligands
and distant members of GFL include GDNF, NRTN, ARTN, PSPN,
and GDF15. They all form homodimer and bind to respective co-
receptor GFRα (1–4) and GFRΑL respectively. The complex of ligand
and co-receptor interacts with RET which leads to phosphorylation of
RET and activation of intracellular signalling cascades. GDNF can also
signal through alternate receptor NCAMand syndecan-3 (GDNF,NRTN,
and ARTN). GDNF signalling is important for survival, neurite out-
growth, migration, and differentiation of neuronal cells and regulation
of body weight via appetite control
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Naveilhan et al. 1998; Baloh et al. 1998). Functional GFRα4
is predominantly expressed in the thyroid gland (Lindahl et al.
2001; Vanhorne et al. 2005). These findings suggest that neu-
roprotective and neurorestorative effects of GFLs in the dopa-
mine system are mostly mediated via GFRα1/RET and
GFRα2/RET complexes.
Due to the remarkable support to dopamine neurons pro-
vided by GDNF and NRTN seen in both in vitro and in vivo
studies, several clinical trials in PD patients were conducted.
GFLs do not cross through the blood-brain barrier. Therefore,
these proteins were delivered either as a purified form or by
means of gene therapy directly into the brain using complex
stereotactic surgery. In the first randomized double-blinded
clinical trial, intracerebroventricularly delivered GDNF failed
to produce clinical benefits. However, it was shown that in
this study, GDNF was not able to reach the target tissues,
thereby halting its therapeutic effects (Nutt et al. 2003). The
next small-scale phase I/II clinical trials showed that the direct
infusion of GDNF into the putamen was well-tolerated and
improved motor function and increased [18F]DOPA uptake in
the brains of PD patients (Gill et al. 2003; Slevin et al. 2005).
However, the follow-up double-blinded randomized placebo-
controlled trial with intraputaminal administration of GDNF
failed to reach its primary efficacy endpoints (improvement in
motor function) despite enhanced [18F]DOPA uptake in the
putamen (Lang et al. 2006). The failure of this double-blinded
trial can be explained by the poor tissue distribution of GDNF
which might be due to the difference in the catheter size and
pump design used for the study, and an insufficient number of
patients in the treatment groups (Lang et al. 2006; Hutchinson
et al. 2007). Furthermore, the study conducted in rhesus mon-
keys with the same delivery system as the one used in the
double-blinded trial conducted by Lang and co-authors found
that GDNF was unevenly distributed in the putamen, being
highly concentrated around the catheter tip (Salvatore et al.
2006). The recent randomized placebo-controlled phase II
study and extended treatment paradigm with intermittent
intraputaminal convection-enhanced delivery of a low dose
of GDNF also failed to reach the primary endpoint.
Nevertheless, in this study, post hoc analysis revealed that
43% of the patients in the GDNF group showed a clinically
significant motor improvement. Importantly, all GDNF-
treated patients had increased [18F]DOPA uptake in the puta-
men. The results of these studies also suggested that the use of
a higher dose of GDNF with 80 weeks of total study duration
might result in a significant clinical benefit of GDNF (Whone
et al. 2019b, a).
In order to achieve targeted therapy and continuous expres-
sion of GDNF throughout the target area, a viral vector-
mediated delivery approach has been introduced. In a phase
I open-label study, the adeno-associated virus (AAV) serotype
2-NRTN (CERE-120) delivery to putamen was safe and well-
tolerated, and it improved motor function of PD patients
(Marks et al. 2008). In a double-blinded sham surgery-
controlled trial, injection of AAV2-NRTN bilaterally to
putamina did not lead to a significant difference in primary
endpoints in patients treated with CERE-120 compared to
placebo-treated patients (Marks et al. 2010a, b). However,
modest but significant benefits in the primary outcome com-
pared with placebo controls were seen at 18 months for
AAV2-NRTN treatment (Marks et al. 2010). Later on, immu-
nohistochemical analysis of brains of PD patients and of non-
human primates revealed the interspecies difference in the
distribution pattern of NRTN in the SNpc. Even though
striatal distribution between both species was comparable,
the level of NRTN in the SNpc was drastically lower in
humans compared to monkeys (Bartus et al. 2011). This can
be explained by the impaired axonal transport which resulted
in poor transfer of NRTN into the SNpc in PD patients. To test
this hypothesis, an 18-month double-blinded, placebo-
controlled trial in 51 patients with advanced PD with bilateral
AAV2-NRTN injection into both the substantia nigra and pu-
tamen was conducted. However, no significant differences
between groups in the primary endpoint or in most of the
secondary endpoints were observed. The procedure was
wel l - tolerated with no signs of ser ious adverse
effects (Olanow et al. 2015). Nevertheless, post hoc analysis
revealed a greater benefit in early-stage patients compared to
advanced patients (Bartus and Johnson 2017). Furthermore,
the treatment with AAV2-GDNF in a phase I clinical trial was
found to be safe and well-tolerated, with increased putaminal
distribution of GDNF and enhanced putaminal [18F]DOPA
uptake suggesting neurotrophic effects on dopamine neurons
(Heiss et al. 2019).
In summary, preclinical studies have demonstrated robust
effects of GDNF family neurotrophic factors in a moderate
neurotoxin animal model of PD. However, clinical trials with
GDNF and NRTN have failed to demonstrate statistically sig-
nificant benefits in PD patients. There might be several rea-
sons behind the failure in translation of preclinical outcome.
The tissue distribution of GFLs is limited because of its high
Fig. 2 Schematic representation of healthy and degenerated neurons in
both Parkinson’s disease and neuropathic pain. a Dopamine neuron
projections in a healthy brain are shown in the left hemisphere (yellow)
and in a brain of patient with Parkinson’s disease in the right hemisphere
(gray). b GFL treatments simulate regrowth and restore dopamine fibers
which are shown in the right hemisphere (green). c Sensory neurons
locate in dorsal root ganglia and send their projections to periphery and
to spinal cord in healthy people as shown on the right panel (yellow). d In
neuropathic pain patients, sensory neurons degenerate and loose termi-
nals in both periphery and in spinal cord as shown on the right panel
(gray). Treatment with GFLs protects and restores central and peripheral
projections of sensory neurons and targets them to topographically correct
place in the spinal cord as shown on left panel (green). Arrow heads
indicate the sites of lesions in spinal nerve ligation (SNL) model of NP
and dorsal root crush (DRC) model of experimental neuropathy
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binding affinity to heparan sulfate proteoglycans (Bespalov
et al. 2011). Furthermore, the size of the human brain is much
larger compared to rodent and monkey brains which exponen-
tially decreases the area of tissue diffusion of GFLs. This issue
can be partly solved by using GDNF and NRTN variants
which have been shown to have better tissue diffusion and
stability (Runeberg-Roos et al. 2016; Grondin et al. 2019)
Therefore, these variants can be considered as potential can-
didates for treating PD patients. In addition, problems with
tissue distribution can also be solved by using CDNF, a novel
neurotrophic factor which has been shown to protect and re-
store dopamine neurons in various animal models of PD
(Lindholm et al. 2007; Airavaara et al. 2012; Bäck et al.
2013; Subramanian 2013). Importantly, CDNF is currently
in a phase I/II clinical trial in PD patients (NCT03295786).
However, patients with an advanced stage of PD are
predominantly selected for the clinical trials with NTFs due
to the high invasiveness of the treatment. These patients have
little, if any, dopamine neurons which can be rescued by
GFLs. In addition, the impairment in axonal transport in
late-stage patients might hinder retrograde transport of trophic
factors necessary for the generation of cell survival signals.
Therefore, early-stage PD patients should be selected to ben-
efit from trophic factor therapy. The lack of GFL efficacy in
clinical trials can also be due to low dose and/or low biological
activity of a particular batch of the protein, which might have
been insufficient to provide clinical improvement (Kirkeby
and Barker 2019). Therefore, the design of future clinical trials
with GFL-based drugs in PD patients has to be improved. In
particular, special attention should be given to the selection of
patients into treatment groups. In this regard, ethical pressure
to choose late-stage PD patients and pharmacokinetic issues
can be overcome by the use of systemically delivered small
molecules targeting GFL receptors. These compounds, with
improved tissue distribution, can also have the benefit of
targeting both remaining axons of dopamine neurons in the
putamen and their cell bodies in the SNpc.
Neuropathic pain
Neuropathic pain (NP) is a long-lasting condition occurring as
a result of a disease or lesion in the somatosensory system. It
affects up to 10% of the population (Yawn et al. 2009; van
Hecke et al. 2014), being more common in elderly people and
often appears as a result of trauma, disease, or treatment. The
prevalence of NP is expected to grow in the future because of
population aging and increase in the number of people affect-
ed by conditions causing NP.
The current management of NP is unsatisfactory. Existing
drugs provide adequate pain relief only in a subset of patients
and their use is often accompanied by the development of
tolerance and dependence. Moreover, neither of the existing
treatments is able to eliminate the cause of the disease or in
other words protect and restore the function of injured sensory
neurons (Fig. 2). This indicates the urgent need for the devel-
opment of novel treatments improving the condition of injured
sensory neurons and their function in NP patients.
GFLs in Neuropathic pain
Sensory neurons in dorsal root ganglia (DRGs) express recep-
tors for several neurotrophic factors, in particular neurotrophin
receptors TrkA, TrkB, and TrkC, and GFL receptors GFRα/
RET (Orozco et al. 2001; Usoskin et al. 2015), and, therefore,
respond to neurotrophins and GFLs. In healthy adult rodent
DRGs, TrkA is expressed in approximately 40% of sensory
neurons (McMahon et al. 1994; Orozco et al. 2001), TrkB and
TrkC in 10–20% (McMahon et al. 1994; Orozco et al. 2001;
Lin et al. 2011), RET in 60%, GFRα1 in 40%, GFRα2 in
30%, and GFRα3 in 20–40% of sensory neurons. Nerve in-
jury increases the expression of RET (70%), GFRα1, and
GFRα3, and downregulates GFRα2 expression (Bennett
et al. 2000b; Wang et al. 2011). In healthy human DRGs,
the percentage of cells expressing neurotrophin receptors
and GFRα3 are very similar to rodents’, but the GFRα1–2/
RET expression pattern is different: RET is expressed in ap-
proximately 80% of neurons, GFRα1 in 20%, and GFRα2 in
51% (Josephson et al. 2001). The distribution patterns of GFL
receptors in the somatosensory system, and positive biological
effects of GFLs, in particular GDNF and ARTN, in cultured
sensory neurons, make them attractive targets for the develop-
ment of analgesic treatments.
Neurotrophic factors play an important role in the develop-
ment and maintenance of hypersensitivity and pain.While it is
generally accepted that neurotrophins, in particular BDNF and
NGF, are pronociceptive, reports on the biological effects of
GFLs in the somatosensory system are rather contradictory.
Both GDNF and ARTN were tested in animal models of neu-
ropathic pain.
In injury-based models of experimental neuropathies,
GDNF and ARTN prevented and reversed tactile and thermal
hypersensitivity, and normalized the expression of various
sensory neuron markers. GDNF was also shown to normalize
electrophysiological properties of injured sensory neurons and
the expression of sodium channels (Bennett et al. 1998;
Boucher et al. 2000; Boucher and McMahon 2001; Wang
et al. 2003, 2014, 2017; Hao et al. 2003; Gardell et al. 2003;
Zwick et al. 2003; Pezet et al. 2006; Sakai et al. 2008;
Hubbard et al. 2008; Takasu et al. 2011; Fukuoka and
Noguchi 2015). In addition, intraperitoneally injected ARTN
relieved herpes virus-induced mechanical hypersensitivity
(Asano et al. 2006). Importantly, in the dorsal root crush mod-
el, systemically delivered ARTN promoted the regrowth of
axons and also guided them into topographically correct
152 Cell Tissue Res (2020) 382:147–160
regions of the spinal cord (Wang et al. 2008; Harvey et al.
2010). In these studies, ARTN also induced the regrowth of all
types of sensory afferents into the spinal cord. The effects of
neurotrophins in this model were quite different: they promot-
ed the robust regrowth of only peptidergic fibers into the spi-
nal cord in the absence of topographic targeting. Noteworthy,
ARTN overexpressed from the lentiviral vector in DRGs
failed to promote regrowth of axons into the spinal cord and
the overexpression of this protein in the spinal cord failed to
promote the regeneration of non-peptidergic sensory axons,
while correctly targeting peptidergic ones (Kelamangalath
et al. 2015). The mechanism of topographically correct
targeting of regenerating axons by systemic ARTN is some-
what mysterious. The ARTN ligand-binding subunit, GFRα3
co-receptor, is expressed only in CGRP-positive, peptidergic
sensory neurons in healthy organisms. Nerve lesions also
stimulate the expression of GFRα3 in some non-peptidergic
neurons. For example, it was shown that GFRα2-positive
neurons switch phenotype after the nerve cut, shutting down
GFRα2 expression and becoming GFRα3-positive (Wang
et al. 2011). ARTN can also act via indirect mechanisms by,
for example, increasing the expression of other axon guidance
proteins, such as GDNF. It is also unclear why spinal overex-
pression and systemic delivery had different effects in non-
peptidergic sensory neurons.
The effects of GFLs in inflammatory and cancer pain states
in mice seem to be opposite to the data collected in nerve
injury-based models. Inflammation and cancer modulated
the expression of GFLs in both experimental animals (Toma
et al. 2002; Hashimoto et al. 2005; Malin et al. 2006; Ikeda-
Miyagawa et al. 2015; Ding et al. 2017) and humans (von
Boyen et al. 2006; Ceyhan et al. 2007). The level of ARTN
expression correlated with the severity of pain in chronic pan-
creatitis in humans (Ceyhan et al. 2007). Sequestration of
GFLs with antibodies alleviated complete Freund’s
adjuvant-induced mechanical hypersensitivity (Fang et al.
2003; Amaya et al. 2004; Thornton et al. 2013; Nencini
et al. 2018) and cold allodynia (Lippoldt et al. 2016) in exper-
imental animals and reduced electrical activity of bone mar-
row nociceptors in a model of carrageenan-induced bone pain
(Nencini et al. 2019). However, lentiviral vector-mediated
GDNF overexpression alleviated tumor-induced mechanical
and thermal hyperalgesia (Ding et al. 2017).
Reports of GFL actions in healthy animals are inconsistent.
In many studies conducted in rats, GFLs seem to have no
influence on pain-like behavior (Boucher et al. 2000;
Gardell et al. 2003; Ramer et al. 2003; Yoshida et al. 2011)
although some authors report heat and mechanical
hyperalgesia after repeated ARTN injections (Ikeda-
Miyagawa et al. 2015) or single injection of a high dose of
GDNF (Joseph and Levine 2010). At the same time in mice,
GFL administration causes mainly thermal (Malin et al. 2006;
Lippoldt et al. 2013), but in some studies also mechanical,
hypersensitivity (Wang et al. 2018). Delivery route and ad-
ministration schedule may play a role in hypersensitivity re-
sponses in GFL-treated healthy animals. While subcutaneous
injections were well-tolerated, direct injections of GFLs into,
for example, bone marrow, plantar surface, or intrathecal
overexpression were pronociceptive. Also, single injection
of ARTN in rats (Ikeda-Miyagawa et al. 2015) or subcutane-
ous administration on every other day (Gardell et al. 2003)
produced no pain-like responses contrary to repeated every
day administration (Ikeda-Miyagawa et al. 2015). Poor tissue
distribution of GFLs could have resulted in a very high point
concentration of the protein in the case of local delivery,
which produced detrimental effects on the sensitivity to vari-
ous pain stimuli. Importantly, pronociceptive effects of GFLs
seem to be mainly short-term (although the data of Joseph and
Levine 2010 contradict this statement), which may explain
some discrepancies in experimental results.
The data collected from GFLs and GFL receptor knockin
and knockout mice stress the importance of GFL signalling in
the somatosensory system. Overexpression of GDNF in the
skin could have altered mechanical sensitivity (contradictory
results are presented in Zwick et al. 2003; Albers et al. 2006)
in näive animals, but had no influence on thermal sensitivity,
despite increased density of intraepidermal nerve fibers
(Zwick et al. 2003). ARTN overexpression, accompanied by
the increased number of nociceptors in DRGs, and expression
of transient receptor potential (TRP)V1 and TRPA1 resulted
in hypersensitivity to heat and noxious cold (Elitt et al. 2006;
Shu-Ying et al. 2008). At the same time, knocking out RET in
nociceptors resulted in hypersensitivity to cold (Golden et al.
2010). GFRα2 knockout mice are hypersensitive to thermal
stimulation but have a reduced response to inflammatory pain
in the formalin test and normal tactile sensitivity (Lindfors
et al. 2006). GFRα3 knockout mice have a normal response
to tactile and thermal stimuli, but fail to produce cold
allodynia in response to inflammatory, traumatic, or chemo-
therapeutic nerve injury (Lippoldt et al. 2016). As GFLs are
survival factors for nociceptors and play an important role in
the development of the somatosensory system, it is not sur-
prising that modulation of their expression or the expression
of their receptors can alter thermal and mechanical sensitivity
as a result of, for example, increased number of nociceptors in
DRGs or reduced density of intraepidermal nerve fibers in the
skin.
Pronociceptive effects of GFLs seem to be related to po-
tentiation of ion channel protein TRPV1 and TRPA1 signal-
ling (Malin et al. 2006) and overexpression of nAChR (Albers
et al. 2014) reported in mice. At the same time in rats, one
group reported downregulation of TRPA1 channel activity by
GDNF (Yoshida et al. 2011).
In translational research, animal models are important for
the preliminary stage before clinical trials, however it is even
more important to understand which effects GFLs have in
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humans. ARTN was found to be safe and relatively well-
tolerated in phase I/II clinical trials in patients with neuropath-
ic pain (Rolan et al. 2015; Okkerse et al. 2016). In a random-
ized placebo-controlled double-blinded phase II clinical trial
conducted in patients resistant to treatments with at least two
standard analgesics, ARTN produced significant pain relief
and improved sleep quality assessed by daily sleep interfer-
ence (Backonja et al. 2017). Interestingly, a U-shaped dose-
response curve was seen in patients treated with ARTN: the
lowest dose produced the highest pain relief and the second
most ef f ic ient dose was the highest one tes ted.
Pharmacokinetics studies revealed a direct correlation be-
tween injected dose and ARTN concentration in serum; there-
fore, pharmacokinetic differences are unlikely to explain such
dose-response relations. Since the concentration of ARTN in
target tissue was not analyzed in this trial, the authors could
not completely exclude that the variation in the drug accumu-
lation in the nervous system of patients treated with different
doses produced a U-shaped dose-response, although it does
not seem to be very likely. Importantly, non-linear dose-re-
sponse relations are not uncommon for neurotrophic factors.
The previously published literature, including our findings,
have shown that the survival-promoting effects of GFLs are
dose-dependent, showing an inverted U-shaped dose-re-
sponse curve (bell-shaped) (Hou et al. 1996; Mills et al.
2007; Planken et al. 2010; Saarenpää et al. 2017). Apart from
pharmacokinetics, this can be explained by (i) negative feed-
backmechanisms in signalling cascades overactivated by high
doses of GFLs; (ii) downregulation of GFL receptor expres-
sion; (iii) reduction in the number of cell surface receptors, as
GFL binding leads to internalization of ligand-receptor com-
plex with subsequent degradation or recycling; (iv) biochem-
ical overload of the signalling system with ligand which
causes the binding of each individual GFRα monomer to a
molecule of a ligand leading to inability to dimerize and form
a tetrameric receptor complex (Schlee et al. 2006); and (v)
hyperactivation of phosphatases dephosphorylating RET
and, thus, shutting down RET-dependent signalling (Yadav
et al. 2020).
The main adverse effect of ARTN treatment in patients was
pruritus, also headaches, changes in temperature perception,
and rashes were reported. Most of the adverse effects were
short-lasting and of mild-to-moderate severity. It is important
to mention here that GFLs can signal via other receptors than
RET, in particular NCAM and syndecan-3 (Fig. 1). Sensory
neurons positive for ARTN’s cognate receptor GFRα3 ex-
press RET only in 30% of cases (Bennett et al. 2000a) and it
was also shown that RET-negative TRPM8-positive neurons
mediate cold sensitivity in experimental animals (Lippoldt
et al. 2013, 2016).Moreover, GFRα3 co-receptor is expressed
in Schwann cells, which do not express RET (Thai et al.
2019). This can explain some effects of GFLs in promotion
of bone pain and altered temperature perception. Receptor
expression patterns published by Usoskin and co-authors also
support this conclusion and indicate that while the pruritus is
mediated by RET, cold hypersensitivity can possibly be me-
diated by other receptors (Usoskin et al. 2015). ARTN also
seems to have a role inmigraine (Shang et al. 2016). However,
it is unclear if systemically delivered ARTN could have trig-
gered headache, as it fails to cross the blood-brain barrier.
All these data taken together indicate that GFLs and their
receptors are important targets for neuronal repair in NP states.
However, special attention should be given to the inflamma-
tory status of the patients, delivery route and schedule, tissue
localization, and expression pattern of GFL receptors.
Therefore, compounds selectively targeting components of
the GFL signalling complex can offer advantages in transla-
tional research, producing less side effects in NP patients com-
pared to GFLs themselves.
Targeting GFL receptors with small molecules
for the development of therapeutics
against Parkinson’s disease and neuropathic
pain
GFL proteins play an important role in the survival and repa-
ration of dopamine and sensory neurons and, therefore, hold
promise for disease modification in PD and NP. However,
GFLs themselves have many disadvantages as therapeutically
used drugs. GFLs do not cross tissue barriers and have to be
delivered directly to the action site, which means in, for ex-
ample, PD patient delivery by complicated brain surgery.
They poorly spread in tissues (Salvatore et al. 2006) which
is caused by their high affinity to the extracellular matrix and
cell surface proteoglycans, and therefore, they may fail to
reach target neurons even if delivered to the correct place.
Their production is complicated and expensive. The biologi-
cal activity of the resulting protein can depend on the produc-
tion system (Saarenpää et al. 2017) and vary between batches.
In addition, it can be diminished if the protein is stored or
handled under suboptimal temperatures (> 4 °C).
GFLs also target several receptors expressed rather ubiqui-
tously in different cell types. This can result in undesirable
side effects, such as cold allodynia in response to ARTN in-
jections mediated by non-RET-related signalling or bone pain
produced by the same protein in which Schwann cells ex-
pressing GFRα3 can contribute.
High point concentrations of GFLs produced as a result of
delivery of extremely high concentrations into a specific tissue
and relatively long half-life of GFL proteins or constant over-
expression from viral vectors can be detrimental for the cells
which is indirectly indicated by biphasic dose-response curves
seen in, for example, clinical trials and in cultured cells.
The biphasic dose-response depends upon the endpoint
measured. U-shaped dose-response curves display a strong
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effect of the drug at a low dose, less effect of a drug at an
intermediate dose, and the second increase in effect at a high
dose. Similarly, in the case of an inverted U-shaped dose-
response curve, the effect of the drug at first increases with
increase in dose and then decreases at higher concentrations
(Calabrese and Baldwin 2001). Biphasic dose-response
curves complicate clinical translation as well as interpretation
of efficacy and side effect data in clinical trials.
Existing data for GFLs suggest that they show their effects
in a narrow range of concentrations, being more effective in,
for example, survival promoting at lower concentrations (Hou
et al. 1996; Mills et al. 2007; Planken et al. 2010; Saarenpää
et al. 2017). Individual variability in the expression level of
GFL-binding proteins (e.g., components of the extracellular
matrix) can further complicate interpretation of the data by
producing differences in their concentrations in target tissues
at the organism level. These issues, together with multiple
sites of action and several receptors transmitting GFL signals,
make the selection of safe and efficient doses of these proteins
in clinical trials difficult.
Targeting GFL receptors with small molecules can help to
overcome at least some limitations associated with clinical
development of GFL proteins. Development, optimization,
production, and storage of chemically based drugs are well-
established by the pharmaceutical industry. Such compounds
may spread in tissues well and cross tissue barriers allowing
implementation of non-invasive delivery schemes.
The first molecule which was shown to bind GDNF’s co-
receptor GFRα1 and promote the neurite outgrowth from neu-
roblastoma cells, XIB4035, was discovered by a Japanese
group (Tokugawa et al. 2003). A follow-up study revealed
that XIB4035 itself is unable to activate GFL receptors, but
can enhance the effects of endogenous proteins (Hedstrom
et al. 2014). Topical application of XIB4035 in animals with
streptozotocin- or genetically induced small fiber neuropathy
alleviated loss of thermal nociception, prevented the loss of
intradermal nerve fibers and Remark bundles, and also re-
stored the density of IB4-positive axons in the spinal cord.
In this study, XIB4035 produced no side effects, did not alter
heat sensitivity in näive mice, and had no influence on me-
chanical sensitivity in any treatment groups (Hedstrom et al.
2014). At the same time, the other group reported the devel-
opment of mechanical allodynia in näive mice in response to
XIB4035 delivered intravertebrally while thermal sensitivity
remained unaffected (Hsieh et al. 2018). XIB4035 has not
been tested in PD models.
High-throughput screening of the libraries of chemical
compounds led to the discovery of two classes of structurally
unrelated selective RET agonists (Bespalov et al. 2016;
Sidorova et al. 2017; Mahato et al. 2019a, b; Jmaeff et al.
2020). One class of these compounds, BT compounds, was
shown to support the survival of naïve and toxin-challenged
cultured dopamine neurons (Mahato et al. 2019a) and promote
neurite outgrowth from cultured sensory neurons (Sidorova
et al. 2017). These compounds also alleviated behavioral man-
ifestations of PD (Mahato et al. 2019b; Renko et al.,
manuscript) and neuropathy-induced pain-like behavior in an-
imal models (Bespalov et al. 2016; Sidorova et al. 2017;
Viisanen et al., manuscript). BT compounds also stimulated
release of dopamine in the brain of experimental animals and
protected and restored sensory neuron phenotypes in animal
models of NP. Importantly, these compounds were able to
cross the blood-brain barrier and could, therefore, be delivered
systemically in patients with PD providing potential treatment
options for the most responsive patient population (early-stage
PD patients), which are now mainly excluded from clinical
trials due to ethical restrictions. BT compounds delivered sys-
temically did not influence thermal and mechanical sensitivity
and seem to be well-tolerated by experimental animals
(Sidorova et al. 2017), which is in line with some reports for
GFL (Boucher et al. 2000; Gardell et al. 2003). The absence of
hyperalgesic and allodynic effects of BT compounds can also
be explained by their short half-life and quick elimination,
better tissue diffusion resulting in lower point concentrations,
and lower efficacy compared to GFLs. Further optimization of
BT compounds for their improved biological activity and
drug-like properties can eventually convert them into the
first-in-class disease-modifying therapeutics against PD and
NP.
The second discovered class of selective RET agonists is
yet to be tested in dopamine and sensory systems. These com-
pounds support retinal cells in tissue explants and have better
pharmacological characteristics compared to the BT family
(Saragovi et al. 2014; Jmaeff et al. 2020). They certainly de-
serve testing in PD and NP models in the future.
A molecular modelling approach led to the discovery of a
class of small molecules selectively targeting GFRα co-
receptors and weakly activating RET (Ivanova et al. 2018).
Their biological activity is insufficient to test them in primary
neurons or animal models of PD and NP. However, their
further development can lead to another approach in
supporting the survival and function of GFL-dependent neu-
rons in PD and NP.
Conclusions and future perspective
PD and NP are characterized by malfunction and loss of do-
pamine and sensory neurons, respectively. The lack of drugs
able to protect and restore these neuronal populations pro-
duces a significant challenge for the management of these
diseases. Increasing prevalence of these conditions in the ag-
ing world population makes the development of novel treat-
ments against PD and NP a burning need in current society.
GFLs support dopamine and sensory neurons in the organism
and are attractive but translationally complicated therapeutic
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options for the development of disease-modifying treatments
against PD and NP. Multiple receptors, pleiotropic effects,
biphasic dose-response, delivery, bioavailability, and dosage
issues impede the clinical use of GFL proteins. Small drug-
like molecules selectively targeting specific receptors or co-
receptors in the GFL receptor complex may be a better alter-
native for translational research.
A few small molecular weight GFL receptor complex ago-
nists have been discovered so far. The data from in vitro studies
and animal models of PD and NP indicate that these com-
pounds have promising properties for further preclinical devel-
opment. At the moment, it is unclear which one of the GFL
receptor-targeting strategies is the best for the development of
the drugs against PD and NP. GFL signalling modulators such
as XIB4035 can offer more physiological activation of RET-
dependent cellular processes, but require the presence of an
endogenous ligand to produce the effect. It can be problematic
in patients with PD and nerve injury-inducedNP states, because
in these cases, the connection between neurons and GFL-
producing tissues is impaired or lost. Direct RET agonists can
target cells independently of the GFRα co-receptor expression
pattern, thus affecting a number of neuronal subtypes. They
also should not influence certain cells responsive to GFLs
which do not express RET, e.g., Schwann cells (Thai et al.
2019) or TRPM8-positive neurons, whose activation is solely
responsible for the development of cold allodynia upon ARTN
treatment (Lippoldt et al. 2013, 2016). At the same time, RET is
expressed in several non-neuronal tissues, such as testicles or
developing kidneys; therefore, direct RET agonists can have
effects in these cell types. Similarly, compounds targeting
GFRα co-receptors can produce unwanted effects in cells lack-
ing RET but expressing a co-receptor. Further studies are need-
ed to clarify these issues and develop clinically safe small mol-
ecules targeting GFL receptors.
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